Current state of aromatics production using yeast: achievements and challenges by Liu, Quanli et al.
Current state of aromatics production using yeast: achievements
and challenges
Downloaded from: https://research.chalmers.se, 2021-08-31 18:58 UTC
Citation for the original published paper (version of record):
Liu, Q., Liu, Y., Chen, Y. et al (2020)
Current state of aromatics production using yeast: achievements and challenges
Current Opinion in Biotechnology, 65: 65-74
http://dx.doi.org/10.1016/j.copbio.2020.01.008
N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
Current state of aromatics production using yeast:
achievements and challenges
Quanli Liu1,2, Yi Liu1,2, Yun Chen1,2 and Jens Nielsen1,2,3,4
Available online at www.sciencedirect.com
ScienceDirectAromatics find a range of applications in the chemical, food,
cosmetic and pharmaceutical industries. While production of
aromatics on the current market heavily relies on petroleum-
derived chemical processes or direct extraction from plants,
there is an increasing demand for establishing new renewable
and sustainable sources of aromatics. To this end, microbial
cell factories-mediated bioproduction using abundant
feedstocks comprises a highly promising alternative to
aromatics production. In this review, we provide the recent
development of de novo biosynthesis of aromatics derived
from the shikimate pathway in yeasts, including the model
Saccharomyces cerevisiae as well as other non-conventional
species. Moreover, we discuss how evolved metabolic
engineering tools and strategies contribute to the construction
and optimization of aromatics cell factories.
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Introduction
By rebuilding and optimizing the cellular metabolism,
metabolic engineering enables the enhanced biosynthesis
of native metabolites or heterologous new products using
genetically modified organisms [1]. Such efforts comprise
an attractive alternative for chemical production, which is
generally obtained by non-sustainable processes,
including plant extraction using various solvents and
chemical synthesis. In the last decade, various cellular
platforms, ranging from prokaryotic to mammalian cells,
have been tested for their capacity to biosynthesizewww.sciencedirect.com chemicals, with several demonstrating promise for
producing a wide array of bulk chemicals, value-added
specialty chemicals and pharmaceutical proteins [2–4].
Commercially viable processes using this cell-mediated
approach have subsequently been established for chemi-
cal building blocks 1,3-propanediol and 1,4-butanediol,
flavor enhancer L-glutamic acid and anti-malarial drug
artemisinic acid [5]. Importantly, the community is con-
stantly exploring and expanding the potential production
space using available metabolic engineering strategies.
This includes the recently established budding yeast
strains that were engineered to produce elevated levels
of oleoylethanolamide [6], a phospholipid derivative with
promising pharmacological applications, as well as the
major cannabinoids that have medicinal properties [7].
Aromatics, or aromatic compounds, which typically
contain conjugated cyclic six-carbon structures, are also
traditionally recognized as chemicals of value, due to their
ability to stimulate the olfactory senses enabling their use
as a fragrance. Being a vast group of chemical substances,
aromatics have various applications in the chemical, food,
cosmetic and pharmaceutical industries [8]. Most aro-
matics on the market are produced by petroleum-derived
chemical synthesis or by isolating natural compounds
produced from plants [9]. As a result, there is an increas-
ing demand for new sources of aromatics to be established
which includes more renewable and sustainable pro-
cesses. In this context, microbe-mediated bioproduction
using abundant carbon feedstocks constitutes a highly
promising alternative, and numerous efforts have been
made on developing cell platforms and processes that are
dedicated to aromatics production. Here, we review
the recent advances in research aimed at the de novo
biosynthesis of aromatics in yeasts, including the model
Saccharomyces cerevisiae as well as other non-conventional
species (Table 1). In addition, emerging difficulties in
strain construction and optimization as well as potential
countermeasures are presented and discussed.
Production of aromatics in yeast
The shikimate pathway, which connects the central carbon
metabolism to the biosynthesis of aromatic amino acids
(AAA, L-phenylalanine, L-tyrosine, and L-tryptophan), is
widespread across bacteria, archaea, fungi, algae and plants.
While detailed study and characterization of enzymes and
genetic regulations involved in this key metabolic route
have been well presented and reviewed elsewhere [10], our
first focus will be on the metabolic engineering efforts
recently performed to create yeast platforms capable ofCurrent Opinion in Biotechnology 2020, 65:65–74
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Table 1
Selection of reconstructed de novo biosynthesis of aromatics in yeast systems
Category Aromatics Host Titer and yielda Fermentation type Reference
Phenol derivatives cis, cis-Muconic acid S. cerevisiae 1.2 g/L (Glu); 33 mg/g (Glu) Shake-flask [17]
S. cerevisiae 2.0 g/L (Glu); 13.4 mg/g (Glu) Fed-batch bioreactor [18]
S. cerevisiae 2.1 g/L (Glu); 12.9 mg/g (Glu) Fed-batch bioreactor [13]
S. cerevisiae 2.7 g/L (CCM and PCA, Glu);
51.6 mg/g (CCM and PCA,
Glu)
Shake-flask [15]
S. cerevisiae 1.2 g/L (Glu and Suc) and
5.1 g/L (Glu and Sur with
amino acids
supplementation); 58 mg/g
(Glu and Sur with amino
acids supplementation)
Fed-batch bioreactor [19]
Vanillin S. cerevisiae 45 mg/L (Glu) Shake-flask [20]
S. pombe 65 mg/L (Glu) Shake-flask [20]
S. pombe >100 mg/L (vanillin b-D-
glucoside, Glu)
Shake-flask [20]
2-Phenylethanol S. cerevisiae 1.6 g/L (Glu); 76.6 mg/g (Glu) Batch bioreactor [23]
P. pastoris 1.2 g/L (Glu); 58.5 mg/g (Glu) Shake-flask [24]
Phenylpropanoids p-Coumaric acid S. cerevisiae 12.5 g/L (Glu); 139.6 mg/g
(Glu)
Fed-batch bioreactor [25]
S. cerevisiae 242 mg/L (Xyl); 9.7 mg/g (Xyl) Shake-flask [26]
Flavonoids Naringenin S. cerevisiae 90 mg/L (Glu); 4.5 mg/g (Glu) Shake-flask [27]
Y. lipolytica 898 mg/L (Glu) Fed-batch bioreactor [28]
Kaempferol S. cerevisiae 26.6 mg/L (Glu) Shake-flask [29]
Quercetin S. cerevisiae 20.4 mg/L (Glu) Shake-flask [29]
Fisetin S. cerevisiae 2.3 mg/L (Glu) Shake-flask [29]
8-Prenylnaringenin S. cerevisiae 0.12 mg/L (Glu) Shake-flask [30]
Eriodictyol Y. lipolytica 134.2 mg/L (Glu) Shake-flask [31]
Taxifolin Y. lipolytica 110.5 mg/L (Glu) Shake-flask [31]
Alkaloids Noscapine S. cerevisiae 2.2 mg/L (Glu with Gly
supplementation)
Shake-flask [35]
8-Hydroxygeraniol S. cerevisiae 227 mg/L (Glu) Fed-batch bioreactor [36]
Nepetalactol S. cerevisiae 5.9 mg/L (Glu) Shake-flask [36]
Pseudotropine S. cerevisiae 0.08 mg/L (Glu) Shake-flask [37]
Tropine S. cerevisiae 0.13 mg/L (Glu) Shake-flask [37]
S. cerevisiae 6 mg/L (Glu with amino acids
and Gly supplementation)
Shake-flask [38]
Cinnamoyltropine S. cerevisiae 6 mg/L (Glu with amino acids
and Gly supplementation)
Shake-flask [38]
a Carbon sources used for yeast cultivations, Glu glucose, Suc sucrose, Xyl xylose, Gly, glycerol.de novo biosynthesizing various aromatic chemicals derived
from this pathway (Figure 1). Here, we focus on several
groups of aromatic chemicals, including phenol derivatives,
flavonoids, and alkaloids.
cis,cis-Muconic acid and Vanillin
cis,cis-Muconic acid (CCM) biosynthesis is of high impor-
tance to establish a potential biotechnological process for
generating the precursor for adipic acid, which is widely
used for the production of plastics and which is also
mainly produced by fossil-based and environmentally
unfriendly processes. While bacterial hosts, such as
Escherichia coli has been engineered to produce a high
level of CCM [11], the yeast S. cerevisiae is often
considered as an attractive CCM production host as its
fermentations can be performed at a low pH, which may
facilitate downstream separation. However, only a
trace 1.56 mg/L of CCM was produced by the firstCurrent Opinion in Biotechnology 2020, 65:65–74 proof-of-concept of S. cerevisiae strain, in which three
bacterial enzymes 3-dehydroshikimate (DHS) dehydra-
tase, protocatechuic acid (PCA) decarboxylase, and
catechol dioxygenase were expressed to convert endoge-
nous DHS to the formation of heterologous CCM [12].
Since this initial work, the yield and titer of CCM have
been substantially improved [13–15], more importantly, it
becomes increasingly evident that yeast CCM production
mainly suffers from two factors: (i) low performance of the
CCM-forming enzymes and (ii) metabolic imbalance
between the shikimate pathway and the heterologous
branch. Specifically, the activity of PCA decarboxylase
responsible for PCA decarboxylation was demonstrated
to limit yield coming from the CCM pathway [16],
thus resulting in remarkable buildup of pathway
intermediates. Using an alternative approach, Bruckner
et al. selected a new PCA decarboxylase derived from the
yeast Arxula adeninivorans with the resultant strainwww.sciencedirect.com
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Figure 1
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Schematic illustration of aromatics biosynthesis. Structures of building blocks, key intermediates and representative compounds of phenol
derivatives (blue panel), flavonoids (magenta panel), benzylisoquinoline alkaloids (BIA, green panel), and monoterpene indole alkaloids (MIA, grey
panel) are shown. PAL phenylalanine ammonia-lyase, TAL tyrosine ammonia-lyase. PEP phosphoenolpyruvate, E4P erythrose-4-phosphate, DAHP
3-deoxy-D-arabino-2-heptulosonic acid 7-phosphate, DHS 3-dehydroshikimate, CHA chorismic acid, PPA prephenate, L-Phe L-phenylalanine, L-
Tyr L-tyrosine, L-Trp L-tryptophan, MVA, the mevalonate pathway, DMAPP dimethylallyl pyrophosphate, IPP isopentenyl pyrophosphate, GPP
geranyl diphosphate.generating up to 1.2 g/L CCM and a yield of 31 mg/g
glucose in a shake-flask batch culture [17]. Moreover, a
prokaryotic transcriptional regulator-mediated synthetic
selection system, which enables the coupling of the
abundance of CCM to cell growth, was also recently
developed to rapidly identify CCM high-producing yeast
strains [18]. Here, an identified variant out of a large strainwww.sciencedirect.com library was able to generate approximately 2 g/L CCM
under bioreactor conditions. In S. cerevisiae, DHS produc-
tion is undertaken by the unique pentafunctional enzyme
Aro1, which determines the carbon flux distribution
towards the native AAA biosynthesis and heterologous
CCM pathway. Hence, effective modulation of Aro1
activity should also render more DHS for CCMCurrent Opinion in Biotechnology 2020, 65:65–74
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introduced to destabilize Aro1 protein, which resulted in
remarkable accumulation of the precursor PCA [19].
Further combination of functional FMN prenyltransfer-
ase-coding PAD1, which is responsible for activating PCA
decarboxylase activity, enabled nearly stoichiometric
conversion (95%) of PCA to downstream products.
Indeed, under the fed-batch fermentation conditions,
the optimized strain produced 5.1 g/L CCM with a yield
of 58 mg/g sucrose (supplemented with amino acids),
representing the highest titer and yield obtained for
CCM biosynthesis in yeast to date [19].
The DHS node has also been exploited as an entry point
for the heterologous biosynthesis of vanillin, currently one
of the most widely used flavoring compounds on the
market. With the introduction of only a small number of
exogenous enzymes, including a fungal dehydratase, a
bacterial aromatic carboxylic acid reductase, and a human
O-methyltransferase, Hansen et al. demonstrated the
capacity for vanillin biosynthesis in both S. cerevisiae and
the fission yeast Schizosaccharomyces pombe with titers of
45 and 65 mg/L, respectively [20]. Growth inhibition assay
showed that vanillin was toxic to S. cerevisiae at a concen-
tration less than 0.5 g/L, while vanillin b-D-glucoside (VG)
was non-toxic even at 25 g/L. By further expressing a plant
glycosyltransferase in S. pombe, which converts vanillin to
VG, and this enabled an increase in production of VG at
titers exceeding 100 mg/L [20]. Furthermore, a recent
study by Strucko et al. indicated that the laboratory strain
S288c produced up to 10-fold more VG compared with
that of the industrially relevant CEN.PK strain [21]. Thus,
selection of yeast strain backgrounds should also be
carefully considered in establishing a cell factory for
vanillin or VG production.
2-Phenylethanol
As well as vanillin, the aromatic compound 2-phenylethanol
(2-PE) is also widely used in the foodand cosmetic industries
due to the appeal of its rose-like scent. S. cerevisiae possesses
the endogenous capacity to generate 2-PE by the means of
the Ehrlich pathway, which has been characterized as the
degradation pathway of branched-chain and aromatic amino
acids as well as methionine [22]. For de novo 2-PE biosyn-
thesis, thephenylpyruvatenodefromtheshikimatepathway
represents the key branch point. Very recently, Hassing et al.
reported an engineered yeast strain capable of producing
1.6 g/L of 2-PE with a yield of 76.6 mg/g glucose, represent-
ing the highest yield for de novo produced 2-PE in S. cerevisiae
[23]. Specifically, the expression of pyruvate kinase variants
exhibiting reduced catalytic activity was demonstrated to
improve phosphoenolpyruvate (PEP) supply while down-
regulation of L-Tyrosine (L-Tyr) pathway showed to elimi-
nate the formation of byproduct p-hydroxy-phenylethanol,
with the latter significantly increasing 2-PE production in
S. cerevisiae. Furthermore, by overexpressing key genes
involved in the Ehrlich pathway ARO10 and ADH6, inCurrent Opinion in Biotechnology 2020, 65:65–74 combination with de-regulating the upstream shikimate
pathway, Kong et al. also demonstrated the first de novo
2-PE production using glucose in methylotrophic yeast
Pichia pastoris at a level of 1.2 g/L [24].
p-Coumaric acid and (iso)flavonoids
Unlike the aromatics so far discussed, most of which
have been produced mainly due to their aromas, flavonoid
production has been researched due to their
various favorable human health-related properties, such
as antioxidant, anti-inflammatory, antiallergic, and anti-
oncogenic. These compounds are a diverse group of
phenylpropanoid-derived plant secondary metabolites
with, in most plants, L-Phenylalanine (L-Phe) serving
as the building block for phenylpropanoid biosynthesis,
with another AAA, L-Tyr, taking this role in only certain
flowering plants (partial monocots). During flavonoid
synthesis, para-coumaric acid ( p-HCA) occurs as the
obligatory metabolic intermediate fueling the down-
stream (iso)flavonoids pathways. In S. cerevisiae, p-HCA
production can be enabled by the introduction of specific
plant or bacterial biosynthetic genes with recent system-
atic metabolic efforts resulting in a maximum p-HCA titer
of 12.5 g/L with a yield of 139.6 mg/g glucose [25]. The
best producing strain harbors four lines of distinct genetic
manipulation: (i) the combination of both L-Phe and
L-Tyr-derived p-HCA forming routes, (ii) the inclusion
of inducible promoters to control gene transcription, (iii)
the implementation of a phosphoketalose-based strategy
to enhance the supply of the limiting AAA precursor
erythrose 4-phosphate (E4P), and (iv) further orchestrat-
ing of the carbon flux between glycolysis and the AAA
biosynthesis pathway through promoter engineering of
key gene branchpoints connecting these two pathways. In
addition, the production of p-HCA using xylose, the
second most abundant sugar after glucose, has also been
developed in S. cerevisiae as well. Based on starting with
an evolved xylose utilizing strain, a bacterial tyrosine
ammonia-lyase (TAL) route was introduced together with
overexpression of several important AAA biosynthetic
genes, resulting in the production of 242 mg/L p-HCA
in shake flask cultivation [26]. This engineered
strain provides a platform for further improving the xylose
catabolism to generate diverse phenylpropanoid
chemicals.
Starting with p-HCA and another precursor malonyl-CoA,
a multiple-step process catalyzes the formation of
naringenin, a key intermediate to the biosynthesis of
dihydroflavonols, flavonols, isoflavones and anthocyanins.
In S. cerevisiae, a modular engineering strategy was
applied to improve naringenin biosynthesis using tyrosine
as the precursor. Through stepwise evaluation of the
heterologous naringenin pathway (module 1) as well as
the supply of native precursors malonyl-CoA (module 2)
and L-Tyr (module 3), the final strain produced up
to 90 mg/L of naringenin in shake flask fermentations,www.sciencedirect.com
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However, no positive effect so far was observed with
respect to tuning the biosynthesis of malonyl-CoA, which
has been proposed to act as a limiting factor. Interestingly,
high-level de novo production of naringenin in the oleagi-
nous yeast Yarrowia lipolytica, well-known for its superior
malonyl-CoA-derived fatty acid (FA) biosynthesis, was
recently established through import of a heterologous
pathway in a mutant background [28]. Specifically, the
overexpression of PEX10, encoding a peroxisomal mem-
brane protein required for peroxisome biogenesis, led to
greater supply of acetyl-CoA by b-oxidation-mediated FA
degradation. Subsequent building of enhanced activities
of malonyl-CoA-producing acetyl-CoA carboxylase and
mutated 3-deoxy-D-arabino-heptulosonate-7-phosphate
(DAHP) synthase, in combination with more copies of
naringenin biosynthetic genes, brought about an
impressive 124.1 mg/L naringenin in test-tube fermenta-
tion [28]. This capacity was significantly amplified to
generate 898 mg/L naringenin under optimized fed-batch
bioreactor, the highest titer reported to date in a microbial
host.
Growing efforts have also been made to extend the
flavonoid biosynthetic pathway in order to provide an
alternative source of more commercially valuable
aromatics. For example, the reconstruction of long
biosynthetic pathways, consisting of up to eight plant
genes, resulted in production of 26.6 mg/L kaempferol
and 20.4 mg/L quercetin, respectively [29]. Moreover,
while in combination with additional chalcone reductase
from the legume plant, the de novo biosynthesis of
isoflavonoid fisetin to a titer of 2.3 mg/L was established
in budding yeast for the first time [29]. By introducing
other modifying enzymes responsible for prenylation or
hydroxylation, de novo production of the potent phytoes-
trogen 8-prenylnaringenin and eriodictyol, and taxifolin
were obtained in hosts S. cerevisiae [30] or Y. lipolytica [31],
respectively.
Alkaloids
Alkaloids, comprising a wide array of naturally occurring
secondary compounds, are popularly defined by structur-
ally containing a heterocyclic nitrogen derived from
amino acids. While the beneficial effects of alkaloids have
long been exploited by traditional medicine worldwide,
two subfamilies of alkaloids having particularly medical
application, these are benzylisoquinoline alkaloids (BIA,
including morphinan alkaloids and noscapine) from
opium poppy and monoterpenoid indole alkaloids
(MIA, including vincristine and vinblastine) found in
the Madagascar periwinkle [32]. Among the known
BIA and MIA biosynthetic pathways found to exist
in plants, membrane-bound cytochrome P450 (CYP)
enzymes, responsible for hydroxylation, constitute a
remarkable portion of catalytic enzymes. Thus, the model
eukaryotic microorganism S. cerevisiae, whose nativewww.sciencedirect.com endomembrane system should support appropriate
function of CYPs, has been preferably chosen as the host
for the latter’s heterologous expression. Indeed, pioneer-
ing work has showcased the feasibility of producing
representative BIA opioids [33] as well as key MIA
intermediate strictosidine [34], respectively, in this yeast.
With the availability of biosynthetic genes identified from
Papaver somniferum, Li et al. demonstrated the de novo
production of noscapine, a promising anticancer agent, in
S. cerevisiae [35]. This reconstructed biosynthetic path-
way is composed of dozens of catalytic enzymes from
bacteria, mammals, and especially several plant endoplas-
mic reticulum (ER)-targeted enzymes. Optimization of
both heterologous and host endogenous metabolic
pathways, and fermentation conditions resulted in the
production of 2.2 mg/L noscapine, representing a greater
than 18 000-fold improvement compared with the initial
titers. One of the two basic precursors involved in MIA
biosynthesis is geraniol, derived from the native
mevalonate (MVA) pathway. By compartmentalizing
the geraniol biosynthetic pathway in the mitochondria,
in order to create dedicated geranyl pyrophosphate (GPP)
pool that could not be consumed by the cytosolic
competing pathway, a sixfold increase in geraniol
production was achieved in budding yeast [36]. Further
integration of plant geraniol hydroxylase, geraniol
oxidoreductase, and iridoid synthase, also led to the
substantial generation of downstream MIA precursors
8-hydroxygeraniol at a titer of 227 mg/L in fed-batch
fermentation and 5.9 mg/L nepetalactol under shake flask
conditions, the highest de novo nepetalactol production
reported so far [36].
The sustainable production of other alkaloids, such as
tropane alkaloids (TAs), which play a role in treating
neurological disorders, also draws the attention of the
metabolic engineering community. TAs comprise a
family of more than 200 specialized metabolites, which
are primarily produced in Solanaceous (nightshade)
species. For the biosynthesis of TAs, tropine represents
an important intermediate, which can be further
combined with other molecules, such as L-Phe-derived
phenyllactyl-CoA, to produce downstream TAs. With
known plant TAs biosynthetic information and the newly
characterized enzyme from Anisodus acutangulus, Ping
et al. successfully reconstructed two six-step biosynthetic
pathways leading to the production of 0.13 mg/L tropine
and 0.08 mg/L pseudotropine, key intermediates in TAs
biosynthesis, in S. cerevisiae from simple feedstocks in
shake flask cultures [37]. Interestingly, another research
group independently presented a set of TAs-producing
yeast strains almost at the same time, which not only
exhibited improved performance on tropine biosynthesis
at a titer of 6 mg/L, but was also able to produce
cinnamoyltropine, a non-canonical TA [38]. All these
outcomes collectively provide a platform for further
characterization of TAs-related plant enzymes as wellCurrent Opinion in Biotechnology 2020, 65:65–74
70 Chemical biotechnologyas motivate efforts towards generating medicinal TAs
using industrial fermentation methods.
Challenges and perspectives
So far, the aforementioned efforts and outcomes have
clearly demonstrated the feasibility of converting yeast
hosts to cell factories for the production of various
aromatics, which can be achieved through manipulating
native yeast metabolism or by grafting heterologous bio-
synthetic pathways onto the cell’s endogenous metabolic
network. Despite their promising potential however,
current performance of most generated strains is not at
a level where fermentation-based production represents
an economically viable alternative to traditional methods
in industry. Multiple factors challenge the improvement
of cell growth, product titer, rate of production, and yield
(TRY). These include cellular toxicity of end-products,
low activity and stability of catalytic enzymes, and meta-
bolic imbalances at the levels of the biosynthetic pathway
and across the cellular network. In addition, a lack of key








































Metabolic engineering strategies and tools for improving the phenotypes of
missing genes of aromatic biosynthetic pathways. (II) Protein engineering is
based adaptive laboratory evolution is used to increase chemical tolerance 
synthetic pathways. (V) Application of membrane transporters provides add
consortium is devised to alleviate metabolic burden by means of an artificia
Current Opinion in Biotechnology 2020, 65:65–74 regulation within the metabolic network also handicaps
this process, leading to a lag in the time taken to discover
and elucidate the contribution of potential biosynthetic
pathways in aromatics’ production. Incomplete knowl-
edge in these areas subsequently represents a major
barrier in the construction of yeast cell factories for
new or complex aromatics. However, rapid evolution of
metabolic engineering principles is likely to create
new reliable solutions for existing problems currently
hindering the industrial bioproduction of aromatic
chemicals. In the following sections, we discuss the
development and application of such enabling strategies
and tools (Figure 2).
Omics-driven elucidation of missing biosynthetic
pathways
The identification of important biosynthetic enzymes in
native producers, makes up the foundation for construct-
ing microbe-based production platforms. This is aided by
detailed and reliable omics data, such as genomics, tran-
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throughput DNA sequencing technologies, the disclosure
of new genomes and transcriptomes has begun in the last
decade to be conducted at an unprecedented level. A
great example of this is the One Thousand Plant
Transcriptomes Initiative, which recently released the
vegetative transcriptomes of 1124 species that cover
diverse plants across green plants, glaucophytes and
red algae [39]. Coincidentally, in 2018, the 10KP
(10 000 Plants) Genome Sequencing Project was
launched with the objective of completing the sequenc-
ing and characterizing of representative genomes from
major clades of embryophytes, green algae, and protists
within the next five years [40]. This increasing access to
high-quality plant genomes and the acceleration in prog-
ress related to functional genomics approaches is effec-
tively reshaping our understanding of genetic foundation
underlying plant aromatic biosynthesis. For example,
Dastmalchi et al. reported the screening and characteri-
zation of a pathogenesis-related 10 protein, namely
neopinone isomerase (NISO), which was found to be
able to catalyze the isomerization of neopinone to codei-
none, a presumed non-catalytic conversion in morphine
biosynthesis [41]. The addition of NISO to previously
established opiate-producing S. cerevisiae strains markedly
enhanced the biosynthesis of codeine and morphine, by
reducing the accumulation of structural isomers neopine
and neomorphine. Another prominent example relates to
representative MIA vincristine and vinblastine, which are
clinically applied to the treatment of lung and brain
cancers. By combing in silicon analysis of annotated genes
in the transcriptome from the native producing plant
Catharanthus roseus alongside extensive chemical
investigations, Caputi et al. were able to complete the
biosynthetic pathway for vindoline and catharanthine,
key intermediates in the vinblastine biosynthesis, with
the discovery of two enzymes precondylocarpine acetate
synthase (PAS) and dihydroprecondylocarpine synthase
(DPAS) [42].
Enhancing enzyme activity via protein engineering
Low metabolic activities accompanied by unsatisfactory
chemical titers and yields have been widely observed for
non-optimized heterologous aromatics biosynthesis in yeast
hosts. Two potential reasons may in part contribute to this
phenomenon: (i) being secondary metabolism in most cases,
the enzymes related to aromatics biosynthesis have been
evolutionarily shaped to be much less efficient than those
involved in central carbon and energy metabolism [43], and
(ii) the absence of an appropriate environment in yeast that
could enable the full functionality of expressed enzymes,
that is their usage at 100% capacity [33]. A substantial
improvement in the biochemical kinetics of selected
enzymes is therefore of great importance for expediting
the establishment of cell factories for aromatic compound
production. To enable this improvement, several protein
engineering methods have been applied. These includewww.sciencedirect.com site-directed mutation and random mutagenesis, which
are commonly used to optimize the in vitro activity of
individual enzymes for bioengineering. The ancestral
sequence reconstruction (ASR)-mediated strategy has also
recently emerged as an effective approach for directed
evolution of enzymes [44]. This involved inferring the
ancient protein sequences using evolutionarily related
extant ones, enabling ASR to identify key amino acid
residues that readily influence substrate and/or reaction
specificity, thus promoting the isolation of new enzyme
mutants which may exhibit beneficial properties by
medium-throughput or even low-throughput screening.
Besides, reconstructed ancestors are believed to possess
higher structural stability and enzymatic evolvability
compared to the contemporary counterparts, thus compris-
ing appealing starting points for delineating the protein
engineering space. Recent application of ASR has indeed
revealed that this approach could substantially improve the
biological activity and stability of coagulation factor VIII [45]
or generate highly functional thermostable enzymes [46].
Alternatively, the metabolic activity of biosynthetic
enzymes or pathways can be optimized in vivo. This is
by the means of metabolite-responsive biosensors [47],
which transform changes in chemical production to
readily quantifiable factors, such as a fluorescence signal.
By repurposing the TtgR regulatory protein to a resvera-
trol-responsive biosensor in E. coli, Xiong et al. demon-
strated the rapid and efficient selection of resveratrol
hyper-producers and identification of Arabidopsis thaliana
p-coumarate:CoA ligase (4CL) variants displaying
improved catalytic properties relative to wild type for
the production of this aromatic compound [48].
Furthermore, the best 4CL mutant was found to be
applicable for increasing production of naringenin. Simi-
larly, in S. cerevisiae, the development and characteriza-
tion of a naringenin-induced biosensor afforded the
efficient optimization of a naringenin associated biosyn-
thetic pathway [49], in which a strain library featured by
the combinatorial assembly of biosynthetic genes and
promoters has been screened. On the other hand in
addition, intensive investigations towards characterizing
the outstanding variety of plant secondary metabolism,
have shown it increasingly evident that metabolons,
weakly bound and ordered protein complexes composed
by sequential biosynthetic enzymes, play a crucial role in
maximizing the channeling of metabolic intermediates
and reducing undesired metabolic cross-talk [50,51].
Hence, mimicking this protein interaction in yeast hosts,
either by simple peptide linkers [52] or synthetic protein
scaffolds [53], should significantly reduce the buildup of
intermediates or byproducts thus fully releasing the bio-
synthesis potential of aromatics originating from plants.
Host engineering towards improved phenotypes
The biosynthesis and accumulation of heterologous
chemicals frequently exert dramatic cytotoxicity,Current Opinion in Biotechnology 2020, 65:65–74
72 Chemical biotechnologypotentially decreasing the cellular fitness and metabolic
robustness of engineered cell factories. For example, a
few aromatics, such as 2-PE [23] and vanillin [20], are
known to be inhibitory to cell proliferation of yeast hosts
even at levels less than gram-per-liter. However, consid-
ering the anti-microbial and anti-oxidative properties of
flavonoids, it may come as no surprise that cytotoxicity
might occur when pursuing their high-level production in
yeast strains. Accordingly, multiple lines of strategy,
including adaptive laboratory evolution (ALE) and
transporter engineering, have been devised to alleviate
the issue of product toxicity, concomitant with improving
the chemical production titer and yield.
By leveraging a key mechanism in evolution natural selec-
tion, ALE offers an emerging but increasingly important
approach to rapidly generating novel microbial phenotypes
[54]. This strategy, wherein phenotype of interest is
coupled to cell growth, also capitalizes on recent develop-
ments in multi-omics techniques and genome engineering
to help identify underlying genetic mechanisms in the final
evolved strains that contain improved phenotypes. With
the establishment of this powerful fitness selection system,
through which adaptive mutant strains are enriched, ALE
can be applied to improve microbial hosts performance in
four ways: (i) substrate utilization, (ii) increasing tolerance,
(iii) growth rate optimization, and (iv) increasing product
biosynthesis. For example, the tolerance mechanisms
adopted in S. cerevisiae to tackle cellular stress imposed
by inhibiting concentrations of dicarboxylic acids, includ-
ing adipic acid, were recently investigated by Pereira
et al. principally using ALE experiments [55]. Detailed
genome sequences analysis indicated that yeast
membrane transporters play a key role in affording strains
evolved tolerance, with the overexpression of identified
multidrug transporter-coding gene QDR3 in particular
showing to be beneficial to cis, cis-muconic acid biosynthe-
sis in an engineered S. cerevisiae host. Interestingly,
membrane transporter was also genetically associated with
p-HCA tolerance in the soil bacterium Pseudomonas putida
KT2440, an isolate exhibiting native tolerance to various
types of stress [56]. These findings imply that engineering
membrane transporters may provide additional driving
force for high-level chemical production using microbial
systems, in particular for those that tend to accumulate
intracellularly, such as methylated flavonoids [57]
which have also been engineered for their production in
S. cerevisiae. In addition, the rational selection and applica-
tion of transporters from different organisms, have been
employed for both enhancing the biosynthesis of fatty
alcohol [58] and for the efficient transport of dicarboxylic
acids [59] in S. cerevisiae, represents a promising alternative
strategy to enhance chemical producing capability.
Metabolic burden, resulting from the competition
between chemical production pathways and native
metabolism for building blocks (including chemicalCurrent Opinion in Biotechnology 2020, 65:65–74 precursors, energy molecules, and reducing equivalents),
exists as one of the major challenges during current
recombinant strain construction and optimization. The
cell consortium is one such approach devised to alleviate
metabolic burden in a single host by dividing the labor
among several, by means of an artificial microbial
community. This innovative approach has shown to dras-
tically improve metabolic efficiency compared to the use
of monoculture, with Jones et al. recently providing one of
the first reports using this approach to enable substantial
de novo production of the anthocyanin molecule caliste-
phin [60], a previously recalcitrant metabolic engineer-
ing target, by building and optimizing a synthetic, 4-strain
E. coli polyculture that collectively performed the
function of 15 unique heterologous or modified enzymes
from diverse plants and other microbes. Although as
yet unreported, it is anticipated that similar coculture
approach, using artificial microbial communities to
divide the chemical production workload, should be
applicable for engineering aromatics production in yeast,
especially for those derived from lengthy biosynthetic
pathways, on the premise that the efficient transport of
intermediates could be solved.
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